VYNE logo.jpg
VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
06 mai 2021 07h00 HE | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the first quarter ended March 31, 2021 and...
VYNE logo.jpg
VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021
28 avr. 2021 08h00 HE | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the first quarter...
VYNE logo.jpg
VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences
04 mars 2021 16h01 HE | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and...
VYNE logo.jpg
VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update
04 mars 2021 07h00 HE | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the fourth quarter and year ended December...
VYNE logo.jpg
VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference
01 mars 2021 16h01 HE | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and...
VYNE logo.jpg
VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis
01 mars 2021 08h00 HE | VYNE Therapeutics Inc.
Announces promising preclinical data on FMX114 Phase 2a clinical study in AD expected to begin in 3Q 2021 with top-line results by year end Further details on FMX114, including clinical...
VYNE logo.jpg
VYNE Therapeutics to Report Financial Results for the Year Ended December 31, 2020 on March 4
23 févr. 2021 08h00 HE | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the year ended...
VYNE logo.jpg
VYNE Therapeutics Announces Reverse Stock Split
11 févr. 2021 08h00 HE | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of...
VYNE logo.jpg
VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update
01 févr. 2021 08h00 HE | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
VYNE logo.jpg
VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update
29 janv. 2021 08h00 HE | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct...